Structure Therapeutics Reports the First Patient Dosing in P-IIb (ACCESS) Trial of GSBR-1290 for Obesity
Shots:
- Structure has dosed the first patient with GSBR-1290 in P-IIB (ACCESS) trial for obesity or weight-related comorbidities
- The P-IIb (ACCESS) trial and P-II (ACCESS II) study aim to evaluate GSBR-1290 in adults with obesity or weight-related comorbidities, with ACCESS testing 5mg, 45mg, 90mg & 120mg in 220 subjects while ACCESS II evaluating 5mg, 120mg, 180mg & 240mg in 82 adults for 36wks. (1st patient dosing expected by YE'24). Topline data of both the studies is anticipated in Q4’25
- GSBR-1290 is an oral GLP-1 receptor agonist for obesity and T2DM that selectively activates the G-protein signaling pathway. Structure is also advancing next-gen oral small molecules, incl. amylin receptor agonists & combination GLP-1, GIP, glucagon & apelin agonists
Ref: Structure Therapeutics | Image: Structure Therapeutics
Related News:- Syros Pharmaceuticals Reports the P-III (SELECT-MDS-1) Study Data of Tamibarotene for Treating Myelodysplastic Syndrome
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
